Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent Advances in ALK2 Inhibitors

6 Aug 2021

Abstract excerpt

High Resolution Image Download MS PowerPoint Slide Activin receptor-like kinase-2 (ALK2) is a type I bone morphogenetic protein (BMP) receptor which has a role in biological processes that control the development of bone, heart, brain, and other tissue. Gain of function mutations in ALK2 have been identified in fibrodysplasia ossificans progressiva (FOP) and the childhood brain tumor, diffuse intrinsic pontine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to TGF-β signaling in diseases
Share to Heterotopic Ossification and Related Conditions
Share to Medical Imaging and Pathology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34423181
DOI: 10.1021/acsomega.1c02983

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent Advances in ALK2 InhibitorsPMID 34423181Read ↗

Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.Semantic proximity Read ↗

Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.Semantic proximity Read ↗

Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.Semantic proximity Read ↗

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma.Semantic proximity Read ↗

Recent progress in drug development for fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Recent Topics in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.Semantic proximity Read ↗

Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task ForceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.